Anlotinib Completed Phase 2 Trials for Tumors Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT01874873A Phase II Study of Anlotinib in MTC Patients